Novartis Animal Health has announced the launch of Strenzen, an oral water medication for pigs, indicated for the treatment of gastrointestinal infections caused by Escherichia coli, Clostridium perfringens and Salmonella Typhimurium, and for respiratory tract infections caused by Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
Strenzen contains contains a combination of amoxicillin trihydrate (500 mg/g) and potassium clavulanate (125 mg/g) in ratio of 4:1. Novartis says it is ideally suited for the treatment of post-weaning infections in pigs.
According to the company, the combination of amoxicillin and clavulanic acid broadens the performance of amoxicillin1,2, especially against resistant strains of bacteria capable of producing ß-lactamase enzymes. Certain bacteria are able to produce ß-lactamase enzymes as a protection mechanism, making the amoxicillin molecule ineffective against them. The clavulanic acid in Strenzen binds to the molecules of the ß-lactamase enzyme, ensuring the amoxicillin remains unaffected and free to attack bacteria. Prof. Dominiek Maes, DVM, MSc, MS, PhD, Dipl. ECVPH, Dipl. ECPHM, from the Porcine Health Management Unit of the Ghent University, Belgium said: "Weaning is a stressful event for piglets and there are several opportunistic diseases that can impact them during this period. The challenge with E. coli and S. suis infections is that in many countries there are currently no commercial vaccines available with proper efficacy. I believe Strenzen can indeed be very helpful in managing those infections which are so prevalent after weaning."
Novartis says Strenzen is rapidly excreted, leading to a withdrawal period of one day, which in turn maximizes production flexibility for pig producers. In addition, the water-soluble formulation of Strenzen ensures that treated pigs get a therapeutic dose even when they stop eating, making it an ideal treatment for sick pigs with compromised appetites.
Recent field trials on infected farms in Spain and the Czech Republic demonstrated that Strenzen-treated pigs give better production performance, better economic returns and require less medical intervention3,4,5. The reduction of the overall amount of antibiotics needed to treat severe post-weaning infections not only saves producers the costs of the labour and the medication, but is also important in regard to the development of resistance in bacteria.
Dr. Ulrich Klein, Global Technical Services Manager, Novartis Animal Health said: "With the launch of Strenzen, Novartis Animal Health demonstrates its commitment to continually broadening our product portfolio to address the specific needs of farmers and food producers. Strenzen has the ideal spectrum for the treatment of post-weaning infections, delivering better productivity results than current therapies for those infections."
References
Vetoquinol UK has launched Marbocyl Solo – a one shot treatment for Bovine Respiratory Disease. Marbocyl Solo is a 100mg/ml solution of marbofloxacin given as one injection IM at 8mg/kg. It treats sick animals fast, killing bacteria in one go, therefore minimising lung damage and consequential morbidity. This fast action reduces the risk of the spread of infection. On top of that, Marbocyl Solo has a meat withdrawal of only 3 days (milk 3 days). “Marbocyl is a well proven antibacterial that is extensively used in cattle practice,” explains Alvin Cerely, Marbocyl’s product manager. “Marbocyl Solo is exceptionally well placed for applying ‘concentration killing’ or a‘strike action’ strategy as opposed to a ‘long action’ strategy used by other antibiotics. Marbocyl Solo is available as a separate presentation to Marbocyl 10% to avoid confusion, particularly with farmers, on different dosage regimes and withdrawal periods.”
Marbocyl Solo is available now and details have been mailed to all cattle vets in the UK and Ireland. Please contact your Vetoquinol representative or telephone 0800 169 8197 for more details.
Dunlops has changed its name to Henry Schein Animal Health.
David Hinton, Managing Director said: "As we change our name to Henry Schein Animal Health, we also reaffirm our company's strong commitment to offer a comprehensive array of products and services to help animal health practitioners in the United Kingdom operate more efficient and successful practices, and provide the best quality patient care.
"We have a new name, but we have the same strong team, the same values, and the same dedication to providing excellent service to our customers."
Henry Schein Animal Health’s expanded offerings include VetLink and Thrive. VetLink is a new e-commerce web site system that enables veterinary surgeons to access the growing internet sector, allowing you to sell anything from pet prescriptions to accessories online, to be delivered to your customers’ homes by Henry Schein Animal Health. Thrive is a new veterinary business analysis service that integrates with practice management software to use a Key Performance Indicator based approach that provides insight into a your practice and identifies areas where you can enhance your business.
Animalcare has launched a new broad spectrum fluoroquinolone antimicrobial (Enrofloxacin) which the company says is highly effective in the treatment of a wide range of conditions and easy to inject, with excellent tissue penetration.
Enrocare solution for injection is presented in three strengths: A 25mg/ml (2.5%) injection for dogs, cats and exotic animals including reptiles, small mammals and avian species. The 50mg/ml (5%) injection is licensed for use in cattle, pigs, dogs and cats, whilst the 100mg/ml (10%) injection is licensed for cattle and pigs. In the case of dogs and cats a single daily dose is needed.
Animalcare says it has priced Enrocare competitively. In addition, the range has been launched with three offers: "Buy one get one free on the 50 and 100mg/ml" and "Buy two get one free offer" on the 25mg/ml pack size. These offers will last for four months until the end of September.
In cattle, Enrocare 50mg/ml, given by the subcutaneous route, is licensed for respiratory disease of bacterial or mycoplasmal origin and the 100mg/ml strength is licenced for both respiratory disease and E.coli mastitis (the latter given by slow intravenous injection). According to Animalcare, its low dose volume makes it particularly suitable for the treatment of respiratory disease in calves. In pigs >25kg Enrocare is licensed for the treatment of the respiratory and alimentary tract diseases of bacterial or mycoplasmal origin and multi-factorial diseases such as atrophic rhinitis and enzootic pneumonia.
Tony Liepman, Animalcare Market Manager said: "The recent successful launch of Cephacare flavour raised Animalcare's profile as a supplier of more up-to-date antibiotics and this is our latest addition which offers excellent efficacy at an attractive price."
The company says Salmoporc has been used on German and Polish farms for over 15 years and has proved to be safe and effective in controlling salmonella.
The vaccine can be administered orally in piglets and via subcutaneous injection in sows.
Company vet Dr Rike Schmelz said: "Salmonella in pigs is growing threat and an important zoonotic disease. According to the 2018 European Food Safety Authority (EFSA) report, salmonellosis is the second most reported zoonosis in Europe with over 90,000 cases reported in humans.
"Salmonella typhimurium and monophasic Salmonella typhimurium represented 17 per cent of confirmed human cases in 2017 so constitutes a major risk to humans."
VetSurgeon.org understands the new vaccine is expected in the UK sometime after October, before which it can be obtained under a Special Import Certificate.
Intervet/Schering-Plough Animal Health has launched its complimentary blood testing service that allows practitioners to investigate one of the main infectious causes of early embryo loss in sheep flocks.
The annual subsidised Barren EweCheck diagnostic scheme is available from 1st December 2010 until 31st March 2011 for breeding ewe flocks. The service establishes whether Toxoplasma gondii is potentially implicated in any empty or aborting ewes.
According to the company, data from the Barren EweCheck and FlockCheck 2010 schemes showed that 86% of flocks had been exposed to the toxoplasma parasite at some point before blood sampling. As a result, practitioners were able to give clients receiving a positive diagnosis timely advice on disease control and the benefits of a Toxovax vaccination regime.
The company anticipates full availability of Toxovax in 2011 and says its Barren EweCheck blood sample submission pads are available directly from the company's Veterinary Support Group by calling 01908 685685.
Defra has announced the detection of Bluetongue (Serotype 1) (BTV1) in five imported cattle on a premises near Blackpool in Lancashire.
The animals originated from within the BTV1 and 8 Restricted Zone in the south west of France and were detected as a result of post-import testing carried out by Defra on all Bluetongue susceptible animals arriving from continental Europe. The animals' documentation complied with the EU Bluetongue rules governing the movement of livestock as the movement occurred at least 60 days after they had been vaccinated.
This is the first case of BTV1 infection in the UK and the five animals have been culled as they may pose a disease threat to other animals. One further animal from the same consignment has also been culled. Test results for that animal were positive for bluetongue although it was not possible to determine the serotype.
There is no evidence that BTV1 is circulating in the UK and no additional control zones have been declared.
This response is in accordance with Defra's Bluetongue Control Strategy. The premises are now under restriction while an epidemiological investigation takes place. This will include further checks on the other animals present on the premises.
Chief Veterinary Officer Nigel Gibbens said: "This is the first case of BTV1 infected animals being imported into the UK. Taking into account the epidemiological evidence and the consideration of the risk represented to British livestock, I have taken the decision to cull these animals.
"This incident shows how important it is for farmers to consider potential disease risks when buying stock. Buyers need to consider how best to protect their own businesses and those of their neighbours and make sure they are clear about the stock they are intending to buy."
Defra continues to test all susceptible animals imported to the UK from continental Europe for all strains of Bluetongue and continues to urge industry to consider the risks and check the health and vaccination status of animals when sourcing any animals from within the UK or abroad.
In line with EU legislation, and our UK Control Strategy agreed with industry, control measures are in place in UK and abroad to prevent the spread of Bluetongue from existing zones around Europe:
Merial has announced the launch of Nexus (http://merialnexus.co.uk), a new online information resource which offers large animal vets and Suitably Qualified Persons (SQPs) CPD training modules, webinars, technical articles, product information, marketing tools and support materials.
Victoria Hudson, Marketing Manager for Merial’s Large Animal Portfolio said: "We know that it can be difficult for busy vets and SQPs to find the time to attend CPD sessions in the evenings. Our new Nexus online portal gives access to resources and training modules that can help vets and SQPs stay up-to-date with the latest thinking, best practice, and enhance their knowledge in the field of large animal health at a time that suits them.
"Merial is committed to providing high quality Continuing Professional Development (CPD); bringing the knowledge, expertise and experience which backs up our well-known brands online, to help support professional development."
The Nexus portal includes a range of online courses and modules aimed at SQPS in particular, participation in which can earn AMTRA points. The company says it will be adding further CPD throughout the year, including AMTRA accredited courses.
Merial is offering the chance to win £200 in Amazon vouchers to eligible individuals who register at merialnexus.co.uk from now until the 22nd April 2016.
Public Health England (PHE) is urging veterinary surgeons, nurses, other healthcare professionals and the public to become Antibiotic Guardians by visiting antibioticguardian.com and pledging to make better use of antibiotics, to help make sure they work now and in the future.
The website first asks users to choose whether they would like to make a pledge as a member of the public or as a healthcare professional or leader.
Those who pledge as a Healthcare Professional > Veterinary Practitioner can select one of the following pledges:
Those who pledge as a member of the public can elect to do so as an adult, a family member, a pet owner or a farmer.
The available pledges change according to category and those who respond will be asked if PHE can follow-up to confirm they did keep their pledge.
The campaign forms part of activities that support European Antibiotic Awareness Day (EAAD). Dr Diane Ashiru-Oredope, Lead for EAAD 2014 at Public Health England, said: "Everybody can help to tackle antibiotic resistance and we really urge people to help us do this. There is a lot to be done but we can start by making inroads into inappropriate prescribing.
"There are 2 elements to this. One is that we need patients to not always expect to receive an antibiotic for those self-limiting illnesses which are typically caused by viruses. This generally includes those where the symptoms include coughs, runny noses, muscle aches and fever. And the other is for GPs not to feel pressurised into prescribing antibiotics when they aren't really necessary.
"Community pharmacists and their teams also have a key role and should be seen as the first port of call for many winter illnesses caused by viruses. They can also help to manage patients' expectations by explaining the normal duration of these symptoms, what warning signs to look out for and providing effective over the counter treatments that will help relieve the symptoms.
Nicholas Brown, President at the British Society for Antimicrobial Chemotherapy (BSAC), said: "Recently published research in BSAC's Journal, Journal of Antimicrobial Chemotherapy, confirms that despite government recommendations to reduce prescribing for viral illnesses there are still many GPs who do this. Of course GPs don't want their patients to feel unwell but there are many medicines which are available over-the-counter which can really help to reduce symptoms and make people feel better.
"We want to encourage everyone to self-treat as much as possible when it is safe and appropriate to do so. By using antibiotics only when they are needed we can all help to make sure that we keep our antibiotics working for everyone in the future.
"Antibiotic resistance is one the biggest threats to public health and PHE is delivering 4 key aspects of the 5-year UK strategy to help combat antibiotic resistance. These are improving infection prevention and control practices to reduce the number of infections in patients; optimising prescribing practice, improving professional education, training and public engagement and enabling better access to and use of surveillance data."
Children learn lots of important lessons about life, sickness and death from animals and veterinary practitioners. There seems to be an important role here for the profession to educate adult animal owners why antibiotics need to be used carefully both in pets and in humans.
The recognition, management and treatment of pain in calves was identified by the BVA and the BCVA as a priority animal welfare problem following the launch of the BVA’s Animal welfare strategy last year, with the two organisations working closely together to progress an evidence-based best practice position and set of recommendations for the profession.
The new position statement specifically recommends the use of non-steroidal anti-inflammatory drugs (NSAIDs) in addition to local anaesthesia when conducting disbudding and castration in calves, as these are procedures that have been shown to cause acute pain at the time of the procedure and chronic pain afterwards. Analgesics have been shown to reduce the signs of pain in this post-operative period in a wide range of research studies.
The position also recommends the 'Three Rs' approach to castration and disbudding of calves, advocating that, where possible, these procedures are: Replaced by, for example, selecting polled sires to replace disbudding; Reduced by, for example, appropriate use of sexed semen to reduce the number of male calves requiring castration; or Refined, with the use of analgesics.
BVA President Gudrun Ravetz said: "BVA and BCVA’s joint position further reinforces the profession’s focus as animal welfare advocates, and conveys the need for adequate pain management that is reflective of current scientific understanding of pain recognition and treatment in cattle.
"Existing legislation requires a level of anaesthesia and we would encourage veterinary colleagues and stock-keepers to also discuss appropriate analgesic regimes used so that vets prescribe appropriately licensed NSAIDs and other analgesic medicines as required, as part of ensuring a good life for the animals we farm for food."
The recommendations support the University of Nottingham School of Veterinary Medicine and Science’s study, published yesterday in the Veterinary Record, which has found that calf husbandry procedures were significantly less likely to include the use of analgesics in addition to the local anaesthetic (that is routinely used) for other similarly painful procedures. While local anaesthesia can reduce or eliminate much of the acute pain, chronic pain may still remain once the relatively short duration of local anaesthetic action wanes.
John Remnant, a member of BCVA Board and Clinical Assistant Professor in Farm Animal Health and Production at the Nottingham Vet School, said: "It appears that veterinarians’ awareness of pain in cattle and willingness to use analgesics in general has increased over the last decade. However, whilst this should be commended, the apparent lack of use of appropriate analgesia specifically in calves undergoing routine husbandry procedures such as castration and disbudding requires urgent action. I am delighted that the findings of Nottingham University’s study support BVA/BCVA’s statement."
BVA and BCVA’s joint position paper on Analgesia in calves can be found at: https://www.bva.co.uk/uploadedFiles/Content/News,_campaigns_and_policies/Policies/Ethics_and_welfare/Analgesia%20in%20calves%20BVA%20branded.pdf
Photo: A calf in England, New Forest national park. Jim Champion. Wikipedia.
The review, announced earlier this year, was recommended to RCVS Council by its Standards Committee following its exploration of the implications of new technologies for both animal health and welfare and veterinary regulation.
The main areas under consideration include the provision of 24-hour emergency cover and the interpretation and application of an animal being under the care of a veterinary surgeon.
The initial stages of this review had been drafted for Standards Committee to consider at its meeting on 9 September, where the outline timetable was also discussed.
Standards Committee Chair Melissa Donald, said: "This is set to become one of our most fundamental reviews of RCVS guidance in recent years.
"Considering the complexity of the issues in question, and their importance to animal owners and the professions alike, it is vital that we allow ourselves enough time to ensure this review is as thorough and comprehensive as possible.
"We have a clear responsibility to seek, understand and, where we can, accommodate the opinions and experiences of as many different people from within and around the professions and the public as possible. I would urge my fellow vets and vet nurses to please find some time to consider these issues very carefully over the coming weeks and months, and to send us their views."
The review will comprise several stages and is expected to take around 12 months to complete. The outline timetable, which may be subject to change, is as follows:
October 2019 – January 2020: six-week Call for Evidence, followed by independent qualitative analysis of all evidence received
February – March: Select Committee-style meetings and independent qualitative analysis of additional evidence gathered [NB this stage is subject to Standards Committee requirements, depending on the evidence gathered.]
April – June: Consider all evidence and draft any new policy
July – August: six-week public consultation on draft policy
September – October: independent review of consultation responses, and production of any proposals for change
November 2020: Finalise any proposals for change and publish any new guidance
To support and promote the various stages of the review the College is also planning a programme of stakeholder engagement, and will also provide regular updates on progress to both Council and the wider profession.
Members of the professions and the public will be able to follow the progress of the review via the RCVS website at: www.rcvs.org.uk/undercare
The National Office of Animal Health has released two films to help industry and consumers understand issues surrounding the use of animal medicines in the food chain.
A film made for the food chain industry titled "Animal Medicines in Food Production - The Food Industry Perspective" has been produced to help industry understand the levels of awareness and concerns that consumers have.
A second film, "Animal Medicines in Food Production - Challenging the Myths" is aimed at consumers and looks at some of the myths surrounding the use of animal medicines in livestock production.
Phil Sketchley, Chief Executive of NOAH, said that while the public was generally supportive of the use of animal medicines in farm production, there was a knowledge gap among consumers about the way that medicines were used: "It was interesting to discover how much people knew about medicines in food production. There were some very positive attitudes among consumers, particularly towards the way British farmers care for their animals. But there were still some areas of concern, for example with the belief among a large number of people that growth hormones were still being used on UK farms, despite the fact they have been banned since 1988.
"The industry film should help people involved in food production understand what consumers are thinking when it comes to animal medicines. Animal health and welfare and ensuring sick animals are treated is a big issue, and food producers and retailers need to be able to communicate clearly with consumers on the subject of animal medicines.
"It is important there is transparency on all issues of animal health and welfare."
Intervet/Schering-Plough Animal Health has announced that it has received approval for the intramuscular (IM) route of administration of Nuflor Minidose 450 mg/ml, a florfenicol-containing broad-spectrum antibiotic for the management of bovine respiratory disease (BRD).
Nuflor Minidose was approved initially in 2008 for subcutaneous (SC) use only and the now approved IM administration route is a line extension. According to Intervet/Schering Plough, IM administration (20 mg/kg administered twice, 48h apart) offers additional flexibility for the veterinary surgeon when treating cattle for BRD.
The company adds that Nuflor Minidose is the florfenicol injectable formulation which offers the lowest injection volume, which in particular is practical when treating heavier animals (thereby avoiding large injection volumes). The withdrawal period after IM administration of NUFLOR Minidose is only 37 days and is considerably shorter as compared to 64 days after SC use (40 mg/kg body weight injected once).
Francis Adriaens, Global Marketing Director, Global Ruminants Business Unit at Intervet/Schering-Plough Animal Health said: "Our customers requested the IM claim when Nuflor Minidose was first introduced and we are delighted to be able to recommend this route of administration hence forth."
Nuflor Minidose is indicated for preventive and therapeutic treatment of BRD in cattle caused by Mannheimia haemolytica, Pasteurella multicoda and Histophilus somni susceptible to florfenicol. The presence of the disease in the herd should be confirmed before administering preventive treatment.
A new injectable antibiotic with nil-milk-withhold licensed to treat foul-in-the-foot in a single shot has been launched by Pfizer Animal Health.
Naxcel Cattle's active ingredient is ceftiofur in a patented sustained-release formulation. According to the company, one injection provides a full course of antibiotic therapy, giving seven days of therapeutic blood levels against the majority of inter-digital necrobacillosis ('foul-in-the-foot') pathogens.
Pfizer vet Dave Gilbert says the expectation is that Naxcel Cattle will make on-farm therapy easier and help improve treatment compliance and thereby first treatment success rates, compared to treatments which require repeat injections. "Having the full course in a single injection simplifies treatment protocols and eliminates a number of reasons for non-completion of treatment, such as forgetting a second or third dose, or not giving them because of apparent symptomatic recovery from the condition."
The site of injection for Naxcel Cattle is the subcutaneous area at the base of the ear (see Figures 1 & 2). Injection instructions are supplied in the product pack. Dave Gilbert suggests that provided cattle are adequately restrained during administration the injection technique is simple and straightforward. The dose rate is 1ml/30kg body weight and up to 30ml can safely be given into each site.
Figure 1. Subcutaneous administration of Naxcel Cattle at the posterior aspect of the ear where it attaches to the head (base of ear).Figure 2. Injection location for the subcutaneous administration of Naxcel Cattle at the posterior aspect of the ear where it attaches to the head (base of ear).
The interactive map, which has been launched as part of Ceva’s ‘For Flock’s Sake – Vaccinate!’ awareness campaign, uses data from the company’s on-farm testing for Chlamydophila abortus, the bacterium that causes EAE.
Ceva says the map shows that the disease is present across the UK, although cases may well be much higher than shown, as the map is only based on farms that the company has tested positive for the bacterium.
Positive EAE cases on farms are recorded by county on the map, so farmers can check for EAE in their area.
The map, available at www.eaemap.co.uk, will be updated regularly as new farms test positive for EAE.
Stephenie Clarke, product manager at Ceva Animal Health, said: "Our new EAE interactive map will be updated on an ongoing basis and will be a useful tool to ensure that farmers are up-to-date with EAE cases throughout the UK."
For more information, visit www.eaemap.co.uk, contact your local Ceva Animal Health account manager, call Ceva on 01494 781510 or email: cevauk@ceva.com.
The company says that the composition and dosage of the new product has been optimised for maximum efficacy 1, 2. It offers three-five days on-label treatment options and does not need to be stored in a fridge.
According to Boehringer, the 600mg dose results in a concentration well above MICs for Strep. uberis and Staph. aureus for 24 hours, even after milking, which means it needs to be administered once a day1. In addition, its formulation enables optimum distribution of penicillin throughout the udder2.
Kath Aplin veterinary adviser at Boehringer Ingelheim said: "Traditionally, in the UK, we have favoured broad spectrum mastitis therapy as our first line approach, however in many other European countries, including The Netherlands, Belgium, Sweden and Denmark, penicillin is the treatment of choice.
"For farms with a mixed or unknown mastitis pattern, the traditional broad spectrum approach to mastitis therapy makes sense. However, many vets now have a good knowledge of common mastitis pathogens on clients’ farms and, for those where gram +ve pathogens predominate, penicillin as a first line treatment is well worth considering."
In a field trial assessing the prevalence of mastitis-causing pathogens and clinical cure rates after treatment with Ubropen3, mild and moderate cases of mastitis were treated for three to five days, with the causal pathogen being unknown at the time of treatment.
Kath said: “In 80% of cases of grade one or two clinical mastitis, the causative pathogen was found to be gram +ve and, following treatment with Ubropen, the overall clinical cure rate was 81%".
Ubropen is now available from the usual veterinary wholesalers in boxes of 20 tubes.
References:
The programme gives farmers and veterinary surgeons access to new resources, enabling a coordinated and consistent approach to farmer training in the responsible use of antibiotics.
The development of the AMBP Programme has been led by NOAH in partnership with a group of stakeholders from across the industry including farmers, vets, the Responsible Use of Medicines in Agriculture Alliance (RUMA), the Veterinary Medicines Directorate (VMD), the British Retail Consortium (BRC) and leading academics, to create a training programme for all those working in the sheep, dairy, beef and pig sectors.
NOAH says the programme will raise awareness, knowledge and understanding of antimicrobial resistance (AMR) and help drive best practice in a consistent manner across UK farms when it comes to using antibiotics.
Training modules are available for farmers to access via the NOAH website or directly through an online Lantra eLearning platform.
In addition to the direct farmer offering, veterinary surgeons will also be to access resource materials, enabling them to deliver training to their clients. This veterinary resource centre will follow soon.
NOAH Chair, Gaynor Hillier, said: "We know that there is a real demand for this type of accessible training and we’re delighted to be able to lead the way in making it available.
"This new collaborative, cross-sector strategy on training will support both farmers and vets, demonstrating that our farmers have the skills to use antibiotics responsibly, providing reassurance to consumers and policy makers. NOAH is happy to be building on existing antibiotic stewardship achievements within the farming sector as ensuring best practice is vital to safeguard the future efficacy of antibiotics for us all.”
Biosecurity Minister Lord Gardiner said:
"The UK is at the forefront of global efforts to tackle antibiotic resistance. Recent statistics show there has been a 27 per cent drop in use of antibiotics in food-producing animals in the UK since 2014 - meeting a government commitment two years early.
"Our farmers and vets must be commended for driving down antibiotic use in livestock to this all-time low - setting an excellent example for others around the world to follow. But it is vital we continue making progress.
"We welcome this new responsible use of antibiotics farmer training programme, which will support the animal medicines industry to take another positive step towards tackling resistance, safeguarding antibiotics for future generations."
Photo: Lord Trees introduced the launch event and outlined his support for the AMBP programme.
Birds at two Bernard Matthews breeder sites in Suffolk and Norfolk have tested positive for avian influenza, though not the highly pathogenic H5 or H7 types.
A movement restriction has been put in place by DEFRA, but a cull has not so far been required. The BBC has the full story at: http://news.bbc.co.uk/1/hi/england/7912529.stm
A short survey, which has been emailed to BVA members this week, asks respondents to confirm which Official Controls Qualifications (OCQ(V)s) they currently hold or previously held.
They are also asked to give reasons if they have chosen to drop a particular qualification without revalidating it.
The BVA says members have raised concerns via Council about the OV training and revalidation process, citing time, cost, a lack of relevance and duplication of learning across different modules as reasons for choosing not to renew their qualifications.
The BVA plans to take the data and insights captured in the survey to the Animal and Plant Health Agency (APHA) and make recommendations for how the system can be made more user-friendly and fit for purpose.
John Fishwick, BVA President, said: "Official Veterinarians have a critical role to play in upholding high standards of health and welfare across the supply chain, certifying products for export and safeguarding against disease and food fraud. We are already aware that this area is facing significant challenges as Brexit is likely to drive up demand for product certification.
"It is particularly worrying to hear that members are finding the system both frustrating and resource-intensive. Losing skilled professionals now at a time when they are needed most would be a real waste of specialist knowledge and could leave gaps in the UK’s provision for responding to disease outbreaks and meeting export certification needs post-Brexit.
"We understand and support the need to keep veterinary skills up to date, but the process for demonstrating this must be straightforward and proportionate. BVA will ensure that all insights offered by respondents are raised with APHA with the aim of getting the system right for OVs working in the UK both now and in the future."
BVA members can access the survey at https://www.surveymonkey.co.uk/r/7Y2Y3RR. The deadline for responding is 29 June 2018.
During the webinar, panel contributors Fiona Lovatt (past president of Sheep Veterinary Society), Jenny Hull (Black Sheep Farm Health, Northumberland), Lesley Stubbings OBE (lead member of SCOPS and independent sheep consultant), and Phillippa Page, (independent sheep vet consultant) will discuss:
The first 250 delegates to sign up will receive a copy of the In Practice supplement as well as a Zolvix notebook and pen.
https://app.livestorm.co/elanco-animal-health/flock-health-in-practice-webinar
The ioLight microscope fits in a jacket pocket and the company says it is both simple to use and robust. It unfolds to record and share 5MP still images and real time HD video at a magnification of x200 on an iPad Air. The resolution is 1 micron or 1/1,000 mm, powerful enough to see the structure of plant and animal cells.
The microscope uses standard microscope slides and has adjustable top and bottom illumination for use on both biological and opaque samples.
Iolight says it is particularly good for live samples which deteriorate on the journey back to the lab, and it works anywhere, even without a WiFi or mobile phone network.
Andrew Monk, who founded ioLight with business partner Richard Williams, said: "It takes just a couple of minutes to get a great image on the microscope, anywhere from a river bank to a factory floor. This makes microscopy simpler for everyone, from experienced professionals to student scientists."
The ioLight microscope can be ordered now from www.iolight.co.uk, priced at £840 including VAT.
In 2014 ioLight co-founders, Oxford physicists Andrew Monk and Richard Williams, filed a patent application for a pocket-sized digital microscope with a performance that compares with expensive laboratory microscopes. They asked Cambridge Industrial Design to realise the product, briefing them that the device would need to deliver images with one micron resolution (required to view human or animal cells) onto a smartphone or tablet, be pocket-sized, easy to use, and economical to build in medium to high volumes.
One of the biggest challenges was in making the unit pocket-sized, which meant it had to be foldable, something which could have led to a loss in the rigidity needed to achieve high resolution images. This challenge was overcome with the use of a single hinge which the company says makes the ioLight both portable and robust.
Alex Jones, Managing director of Cambridge Industrial Design said: "We recognised immediately this was a great idea but the design brief was certainly a challenge. Fortunately, challenges can sometimes bring out the best in designers. The final design is a real success both aesthetically and ergonomically, and this award is a fantastic acknowledgement for the design process and the final product that we have created together with ioLight."
ioLight is also celebrating another success: closing its second round of equity funding after raising £320k from 335 investors on the Crowdcube platform (128% of the initial target).
The company says the new funding will allow it to promote the microscope to a wide range of target markets including veterinary surgeons, education, laboratory and field research, museums and public engagement as well as to international markets.
Andrew Monk, ioLight’s co-founder said: "The product is so simple to use that it is the ideal communication tool for explaining science to the public, students and customers. The microscope lets everyone see the same image so the discussion is about the picture not the tools. It’s a perfect fit for government public engagement campaigns, which are well funded at the moment. We are absolutely delighted that this funding provides us with the opportunity for both product development and to reach out and make microscopy available to so many more people."
Pfizer VPS has launched a 'Pre-Sale Scab Treatment Certificate' so that sheep treated for sheep scab and protected against re-infestation beyond their autumn sale date can be formally certified as such.
A choice of two moxidectin-based treatments are eligible for use, one with 28 days and the other 60 days licensed persistency against the scab mite.
Pfizer VPS vet David Bartram explained that following treatment, the sale date must fall within the persistency window: "The idea is that farmers present their certificate at markets on sale day, then auctioneers announce the scab-protected status during their sales patter. Whether this adds to the sale price will be interesting to find out, but it's sure to be seen as a valuable attribute by buyers who won't need to treat for scab when they arrive home."
Details of the certification process are available from SQPs at animal medicine suppliers. The two eligible treatments are CYDECTIN 1% LA and CYDECTIN 2% LA for sheep.
The EU Commission has approved the marketing authorisation variation of Boehringer Ingelheim's PCV2 vaccine Ingelvac CircoFLEX. This approval allows the combined use of the pig vaccines Ingelvac CircoFLEX and Ingelvac MycoFLEX in the European Union.
Boehringer says it will market this unique vaccine concept under the name FLEXcombo. The company highlights that protection against two of the most prominent and costly pig diseases, Porcine Circovirus Disease (PCVD) and Enzootic Pneumonia, can now be achieved with a single injection instead of up to four injections. More than 70% of European pigs are currently vaccinated against both these diseases.
According to the company, the combined use of Ingelvac CircoFLEX and Ingelvac MycoFLEX is already registered and widely used in North America and Asia. It is globally the first and only product combination of its kind.
Dr. Joachim Hasenmaier, global head of Animal Health within BI said: "We are very proud that we can now also supply EU veterinarians and farmers with this latest innovation that will help tremendously in reducing the number of injections to pigs, supporting the wellbeing of the animals and the farm economics by saving a substantial amount of labour."